OneMedNet (NASDAQ: ONMD): Unlocking the Future of AI in Real-World Data for Healthcare

Update: Big News from ONEMEDNET and PALANTIR 10/06/25

Introduction: Data is the New Gold

Current Price: $0.91/Share

In healthcare, breakthroughs rarely happen in isolation. The drugs, devices, and algorithms that change lives are fueled by something more fundamental: data. Every MRI, X-ray, and lab result holds insights that—if properly unlocked—can accelerate discovery, validate treatments, and ultimately improve patient outcomes.

This is where OneMedNet (NASDAQ: ONMD) comes in. Unlike biotech firms betting on a single therapy, or big pharma giants spending billions on drug development, OneMedNet plays a different game. It supplies the picks and shovels for the healthcare AI and research revolution: regulatory-grade, de-identified imaging Real-World Data (iRWD™).

By transforming underutilized medical imaging into structured, AI-ready datasets, OneMedNet enables life sciences companies, medical device makers, insurers, and AI developers to innovate faster and smarter. In many ways, ONMD isn’t just a healthcare technology company—it’s becoming the connective tissue of a rapidly expanding $60 billion Real-World Evidence (RWE) market.

What OneMedNet Actually Does

Hospitals and clinics generate staggering amounts of medical data every day: CT scans, MRIs, X-rays, ECGs, EHRs, and claims records. Much of it is archived in siloed systems, rarely used beyond the patient’s immediate care.

OneMedNet bridges this gap. Here’s the simplified process:

Partnerships with Hospitals – ONMD partners with hospitals and provider networks, gaining access to massive imaging archives.
De-Identification & Curation – Patient data is stripped of personal identifiers, cleaned, standardized, and organized into regulatory-grade datasets.
Licensing to Customers – Pharmaceutical companies, AI developers, medical device firms, insurers, and researchers license this curated data for clinical research, regulatory filings, and model development.
Revenue Sharing – A portion of licensing revenue flows back to hospital partners, creating incentives for network growth.

The result is a scalable platform where more hospitals mean deeper data pools, and more customers mean recurring revenue streams.

Market Context: Why RWD and RWE Matter

Healthcare is evolving toward data-driven decision making. Regulators like the FDA and EMA now actively encourage the use of Real-World Evidence (RWE) derived from Real-World Data (RWD) to accelerate approvals. Instead of waiting years for trial results, RWE allows companies to:

Discover unmet medical needs.
Validate drug or device effectiveness in real-world populations.
Shorten regulatory review timelines.
Reduce costs of traditional trials.

The FDA has gone so far as to issue formal guidance on using EHRs and claims data in regulatory submissions, underscoring the agency’s support for this shift. In this landscape, OneMedNet’s ability to deliver FDA-ready, regulatory-grade imaging datasets is a significant competitive edge.

And the market opportunity is enormous. According to McKinsey, AI and RWE together could unlock $60-110 billion in annual value for pharma and medical product companies. That means ONMD isn’t just participating in a trend—it’s sitting at the intersection of two megatrends: healthcare digitization and generative AI adoption.

Recent Developments: Signs of Momentum

2025 has been a transformative year for OneMedNet. Key milestones include:

Strengthened Balance Sheet
- Raised $3.7M in private placements at $0.42 per share, including insider participation.
- Reduced liabilities by ~80% since December 2024, settling or converting $11M in Q2 alone.
- Eliminated the last Yorkville Advisors convertible note, cleaning up its capital structure.
Network Expansion
- Grew iRWD™ provider network to 1,750+ sites, encompassing 136M exams, 34M patients, and 5B+ records.
- Added 85 cardiovascular centers, building one of the largest CV data networks in the world.
Strategic Partnerships
- Partnered with Circle CVI to provide regulatory-grade cardiovascular imaging and data.
- Positioned as a leader in multimodal data (imaging, ECG, structured reports) for diagnostics, therapeutics, and AI.
Financial Highlights
- Reported Q2 net income of $3.0M and 1H 2025 net income of $1.1M.
- Posted $0.07 EPS for the quarter ending June 30, 2025.
- Maintains a strategic holding of 15 BTC (~$1.6M) on its balance sheet.

These results demonstrate not only operational progress but also a financial turning point. After years of small revenues and high burn, ONMD is now showing positive net income, reduced debt, and insider confidence through capital participation.

Why This Could Be a Breakout Stock

Several structural factors make ONMD particularly intriguing to investors:

Low Float – With only 25.6M shares tradeable, modest buying interest can move the stock significantly.
High Insider Ownership – At 46.7% insider ownership, management is heavily aligned with shareholder interests.
Massive Market Tailwinds – Healthcare AI, clinical trials, digital health, and regulatory trends all converge here.
Recurring Revenue Model – Enterprise data licensing provides predictability and scalability.
Positive Momentum – Trading above both its 50-day ($0.52) and 200-day ($0.72) moving averages, suggesting technical strength.
Recent Insider Buying.

When combined, these factors position ONMD as a potential “under-the-radar” healthcare data play with asymmetric upside.

CHART: Trading above moving averages looking for a golden cross in the near-term.

stock chart ONMD

The Competitive Edge

Unlike many health data companies that focus primarily on structured EHR or claims data, OneMedNet specializes in medical imaging, one of the most complex and underutilized data types in healthcare. Its proprietary iRWD™ platform offers:

Regulatory-grade datasets trusted for FDA submissions.
Specialization in imaging (CT, MRI, PET, etc.) where data is high-value but rarely leveraged.
Longitudinal patient tracking, enabling outcomes research and post-market surveillance.
AI-ready infrastructure that supports next-generation applications.

This specialization builds a competitive moat. Imaging is technically challenging, requires large-scale storage and standardization, and demands robust de-identification protocols. Few competitors operate with the same depth or regulatory focus.

Risks and Considerations

Investors should also remain clear-eyed about risks:

Small-Cap Volatility – At a $43M market cap, ONMD trades more like a startup than a mature firm. Volatility is high.
Execution Risk – Scaling provider partnerships, maintaining compliance, and delivering consistently high-quality data are operational hurdles.
Dilution Risk – Though recent financings have improved the balance sheet, future capital raises could dilute existing shareholders.
Competitive Pressure – Larger data and cloud players (e.g., IQVIA, Oracle, AWS Healthcare) may expand aggressively into this space.

That said, ONMD’s high insider ownership and growing revenue base suggest management is working to mitigate these risks while aligning closely with shareholders.

Case Study: A “Picks and Shovels” Strategy

Investing in OneMedNet is not like betting on a single biotech’s drug approval. Instead, it’s a picks-and-shovels play—selling essential infrastructure to the entire industry. Whether or not a particular drug succeeds, ONMD still benefits because its data is required across trials, validations, and regulatory submissions.

This business model dramatically reduces exposure to binary outcomes (like failed clinical trials) while capturing upside from the broader healthcare AI and RWE market growth.

The Outlook

CEO Aaron Green summarized the company’s trajectory best:

“The second quarter marked a turning point for OneMedNet. With a stronger balance sheet, an expanded iRWD™ network, and partnerships like Circle CVI, we are well-positioned to deliver long-term value to our customers, partners, and shareholders.”

Looking forward, ONMD’s focus is clear:

Continue expanding the provider network, deepening data coverage.
Build recurring revenue streams through enterprise licensing deals.
Strengthen partnerships in high-value verticals like cardiovascular research and AI.
Maintain financial discipline while scaling operations.

If successful, OneMedNet could evolve into a foundational player in the $60B+ RWE ecosystem, providing the indispensable data layer powering biotech, pharma, and MedTech innovation.

Bottom Line

OneMedNet (NASDAQ: ONMD) occupies a unique position at the crossroads of healthcare, AI, and regulatory science. By unlocking vast archives of imaging data, curating it into FDA-ready datasets, and licensing it to life sciences and healthcare innovators, the company provides the backbone behind smarter trials, faster approvals, and better patient outcomes.

With an expanded iRWD™ network, positive earnings momentum, high insider ownership, and strengthening market tailwinds, ONMD represents both a speculative growth story and a potential long-term enabler of the AI-driven healthcare revolution.

It’s not biotech. It’s not big pharma. It’s the infrastructure behind both—and that could make all the difference!

Your friend,

Steve Macalby

Disclaimer and About Us

Best Growth utilizes a revolutionary fusion of AI-powered analytics and human-led research to distill the vast and complex world of stock trading down to its purest essence. Designed to identify situations before a major move. Our proprietary AI, meticulously performs fundamental, sentiment analysis, scrutinizes an extensive array of data points and trends, providing deep, insightful, and timely market perspectives. This technology operates in concert with our seasoned research team, who apply years of industry knowledge and expertise to refine our AI’s results. The culmination of this unique blend of cutting-edge technology and human expertise is the weekly issuance of one to two stock ideas, carefully selected to offer what we believe will yield the most substantial near-term results thus paving the way for intelligent trading that delivers tangible value. Available exclusively by email or SMS/text message via our newsletter.

Best Growth is your ultimate destination for reliable and insightful stock news and analysis. We are dedicated to providing you with the latest updates and in-depth coverage of the world’s most promising growth stocks. Our experienced financial experts and market analysts work tirelessly to bring you the most accurate and up-to-date information.

At Best Growth, we understand that the investing world can be complex and intimidating. That’s why our primary goal is to simplify the process for you, offering easy-to-understand news articles, market reports, and expert commentary. Whether you are a seasoned investor or just starting your journey in the stock market, we strive to cater to your needs by presenting information in a clear and concise manner.

Our commitment to excellence extends to the quality of our content. We pride ourselves on delivering accurate, objective, and fact-based news and analysis. Our team follows a rigorous editorial process to ensure the highest standards of journalistic integrity.

At Best Growth, we believe in the power of knowledge and education. We go beyond simply reporting stock news; we provide third-party educational resources and investment guides to help you navigate the complexities of the market. We aim to empower you with the knowledge and tools necessary to achieve your financial goals.

We also understand that time is of the essence when it comes to stock analysis and news. That’s why we offer a user-friendly platform that ensures you have quick and easy access to the latest information. be sure you are subscribed to our newsletter and text alerts. Whether you prefer browsing our website or accessing our content through our free or premium subscription, we strive to make your experience seamless and convenient.

We value our community of readers and investors, and we encourage active engagement and participation. Feel free to share your thoughts and contribute to the discussions on our platform (coming soon). We believe that a vibrant and diverse community of investors can enhance the learning experience for everyone involved.

Thank you for choosing Best Growth as your go-to source for reliable stock news and analysis. We are committed to serving you with excellence and helping you stay ahead in the dynamic world of investing. Join us on this exciting journey toward financial growth and prosperity!

Sponsored Content Disclosure – In Accordance with the Securities Act Section 17 (b)

Transparency is very important to us. Please read this disclaimer in its entirety to fully understand this segment of our business model.

BestGrowthStocks.com is a wholly owned subsidiary of Media Source LLC, herein referred to as MS LLC.

This website / media webpage is owned, operated, and edited by Media Source LLC. Any wording found on this website / media webpage or disclaimer referencing to “I” or “we” or “our” or “MS LLC” refers to Media Source LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to market and promote public companies. By reading our website / media webpage you agree to the terms of our disclaimer, which are subject to change at any time.

Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use. Part of MS LLC’s business model is to receive financial compensation to promote public companies in an investor relations capacity. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our Websites, Email, SMS, Push Notifications, Influencers, Social Media Postings, Ticker Tags, Press Releases, Online or Phone Interviews, Podcasts, Videos, Audio Ads, Banner Ads, Native Ads, Responsive Ads. This compensation is a major conflict of interest in our ability to be unbiased regarding the publicly traded entities mentioned. Therefore, this communication should be viewed as a commercial advertisement only. Note, we periodically conduct interviews and issue stock alerts that we are not compensated for, these are purely for the purpose of building our brands and other portions of our business model. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct.

Please Note: MS LLC and its employees are not a registered investment advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.

Release of Liability: Through use of this website viewing or using you agree to hold MS LLC, its operator’s, owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information in our website / media webpage is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. We have been compensated four thousand dollars cash via bank wire by Atlanta Capital Partners for this week’s coverage of ONMD to last from 10/06/2025 through 10/09/2025. We were previously compensated five thousand dollars cash via bank wire by Atlanta Capital Partners for coverage of ONMD to last from 09/22/2025 through 09-26-2025. We do not hold any form of equity in ONMD. Furthermore, MS LLC often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. Some of our claims regarding gains could be based on intra-day, pre-market and after-hours trading data.

All information on featured companies is provided by the companies profiled or is available from public sources and MS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead, MS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.

MS LLC is compliant with the Can Spam Act of 2003. MS LLC does not offer such advice or analysis, and MS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in small and micro-cap growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.

The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.

In preparing this publication, MS LLC has relied upon information supplied by its customers, publicly available information, and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, MS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement.

MS LLC is not responsible for any claims made by the companies advertised herein, nor is MS LLC responsible for any other promotional firm, its program or its structure.